LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 229

Search options

  1. Article ; Online: Usefulness of the coagulation indicators in predicting short and long disease-free interval in breast cancer and development of a nomogram.

    Yao, Huibin / Liang, Ying / Sha, Yingjian / Jia, Yongsheng / Shi, Yehui

    Minerva medica

    2024  

    Language English
    Publishing date 2024-02-06
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 123586-2
    ISSN 1827-1669 ; 0026-4806
    ISSN (online) 1827-1669
    ISSN 0026-4806
    DOI 10.23736/S0026-4806.24.09169-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC)

    Yini Sun / Renyu Ding / Hao Sun / Yingjian Liang / Xiaochun Ma

    Trials, Vol 25, Iss 1, Pp 1-

    study protocol for a multicenter randomized controlled trial

    2024  Volume 9

    Abstract: Abstract Background Disseminated intravascular coagulation (DIC) occurs in 30–50% of septic patients and contributes to high mortality in the intensive care unit (ICU). However, there are few proven interventions for coagulation disorder management in ... ...

    Abstract Abstract Background Disseminated intravascular coagulation (DIC) occurs in 30–50% of septic patients and contributes to high mortality in the intensive care unit (ICU). However, there are few proven interventions for coagulation disorder management in sepsis. Experimental and clinical data have demonstrated that sepsis could benefit from unfractionated heparin (UFH) treatment. To date, there are no large multicenter trials to determine the safety and efficacy of UFH in septic patients with suspected DIC. Methods A multicenter, double-blinded, placebo-controlled randomized trial is designed to recruit 600 patients who met sepsis 3.0 criteria and suspected DIC. Participants will be randomized (1:1) to receive UFH or saline via continuous intravenous administration for 7 days within 6 h of enrolment. The primary outcome is ICU mortality. The secondary outcome includes 28-day all-cause mortality, the improvement of Sequential Organ Failure Assessment scores, and the incidence of major hemorrhage. Investigators, participants, and statisticians will be blinded to the allocation. Discussion The HepSIC trial is to evaluate the efficacy and safety of UFH on sepsis-related DIC across different areas of China. The small dosage of UFH administration would offer a new potential approach for treating sepsis-related coagulation disorders. Ethics and dissemination Ethical approval was granted by all the ethics committees of 20 participant centers. Results will be disseminated via peer-reviewed publications and presented at conferences. Trial registration ClinicalTrials.gov NCT02654561. Registered on 13 January 2016.
    Keywords Sepsis ; Disseminated intravascular coagulation ; Heparin ; Randomized controlled trial ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2024-01-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial.

    Sun, Yini / Ding, Renyu / Sun, Hao / Liang, Yingjian / Ma, Xiaochun

    Trials

    2024  Volume 25, Issue 1, Page(s) 4

    Abstract: Background: Disseminated intravascular coagulation (DIC) occurs in 30-50% of septic patients and contributes to high mortality in the intensive care unit (ICU). However, there are few proven interventions for coagulation disorder management in sepsis. ... ...

    Abstract Background: Disseminated intravascular coagulation (DIC) occurs in 30-50% of septic patients and contributes to high mortality in the intensive care unit (ICU). However, there are few proven interventions for coagulation disorder management in sepsis. Experimental and clinical data have demonstrated that sepsis could benefit from unfractionated heparin (UFH) treatment. To date, there are no large multicenter trials to determine the safety and efficacy of UFH in septic patients with suspected DIC.
    Methods: A multicenter, double-blinded, placebo-controlled randomized trial is designed to recruit 600 patients who met sepsis 3.0 criteria and suspected DIC. Participants will be randomized (1:1) to receive UFH or saline via continuous intravenous administration for 7 days within 6 h of enrolment. The primary outcome is ICU mortality. The secondary outcome includes 28-day all-cause mortality, the improvement of Sequential Organ Failure Assessment scores, and the incidence of major hemorrhage. Investigators, participants, and statisticians will be blinded to the allocation.
    Discussion: The HepSIC trial is to evaluate the efficacy and safety of UFH on sepsis-related DIC across different areas of China. The small dosage of UFH administration would offer a new potential approach for treating sepsis-related coagulation disorders.
    Ethics and dissemination: Ethical approval was granted by all the ethics committees of 20 participant centers. Results will be disseminated via peer-reviewed publications and presented at conferences.
    Trial registration: ClinicalTrials.gov NCT02654561. Registered on 13 January 2016.
    MeSH term(s) Humans ; Heparin/adverse effects ; Disseminated Intravascular Coagulation/diagnosis ; Disseminated Intravascular Coagulation/drug therapy ; Disseminated Intravascular Coagulation/etiology ; Sepsis/complications ; Sepsis/diagnosis ; Sepsis/drug therapy ; Blood Coagulation Disorders/drug therapy ; Hemorrhage/drug therapy ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic
    Chemical Substances Heparin (9005-49-6)
    Language English
    Publishing date 2024-01-02
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2040523-6
    ISSN 1745-6215 ; 1468-6694 ; 1745-6215
    ISSN (online) 1745-6215
    ISSN 1468-6694 ; 1745-6215
    DOI 10.1186/s13063-023-07853-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Role of pyroptosis in hemostasis activation in sepsis.

    Zhu, Chengrui / Liang, Yingjian / Luo, Yangtuo / Ma, Xiaochun

    Frontiers in immunology

    2023  Volume 14, Page(s) 1114917

    Abstract: Sepsis is frequently associated with hemostasis activation and thrombus formation, and systematic hemostatic changes are associated with a higher risk of mortality. The key events underlying hemostasis activation during sepsis are the strong activation ... ...

    Abstract Sepsis is frequently associated with hemostasis activation and thrombus formation, and systematic hemostatic changes are associated with a higher risk of mortality. The key events underlying hemostasis activation during sepsis are the strong activation of innate immune pathways and the excessive inflammatory response triggered by invading pathogens. Pyroptosis is a proinflammatory form of programmed cell death, that defends against pathogens during sepsis. However, excessive pyroptosis can lead to a dysregulation of host immune responses and organ dysfunction. Recently, pyroptosis has been demonstrated to play a prominent role in hemostasis activation in sepsis. Several studies have demonstrated that pyroptosis participates in the release and coagulation activity of tissue factors. In addition, pyroptosis activates leukocytes, endothelial cells, platelets, which cooperate with the coagulation cascade, leading to hemostasis activation in sepsis. This review article attempts to interpret the molecular and cellular mechanisms of the hemostatic imbalance induced by pyroptosis during sepsis and discusses potential therapeutic strategies.
    MeSH term(s) Humans ; Endothelial Cells/metabolism ; Pyroptosis ; Sepsis ; Hemostasis ; Hemostatics
    Chemical Substances Hemostatics
    Language English
    Publishing date 2023-01-23
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1114917
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Retraction notice to "Hepatocellular carcinoma cells-derived exosomal microRNA-378b enhances hepatocellular carcinoma angiogenesis" [Life Sci. 273 (2021) 119184].

    Chen, Wei / Huang, Li / Liang, Junhua / Ye, Yingjian / He, Shan / Niu, Junli

    Life sciences

    2023  Volume 319, Page(s) 121426

    Language English
    Publishing date 2023-02-18
    Publishing country Netherlands
    Document type Journal Article ; Retraction of Publication
    ZDB-ID 3378-9
    ISSN 1879-0631 ; 0024-3205
    ISSN (online) 1879-0631
    ISSN 0024-3205
    DOI 10.1016/j.lfs.2023.121426
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Trend in Antimicrobial Resistance of

    Liang, Yingjian / Qiu, Lidi / Zheng, Xiaobin / Liu, Jing

    publication RETRACTED

    Infection and drug resistance

    2021  Volume 14, Page(s) 2179–2181

    Abstract: In this report, we analyze the trends in antimicrobial resistance ... ...

    Abstract In this report, we analyze the trends in antimicrobial resistance of
    Language English
    Publishing date 2021-06-10
    Publishing country New Zealand
    Document type Journal Article ; Retracted Publication
    ZDB-ID 2494856-1
    ISSN 1178-6973
    ISSN 1178-6973
    DOI 10.2147/IDR.S318005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Unsupervised construction of gene regulatory network based on single-cell multi-omics data of colorectal cancer.

    Cui, Lingyu / Li, Hongfei / Bian, Jilong / Wang, Guohua / Liang, Yingjian

    Briefings in bioinformatics

    2023  Volume 24, Issue 2

    Abstract: Identifying gene regulatory networks (GRNs) at the resolution of single cells has long been a great challenge, and the advent of single-cell multi-omics data provides unprecedented opportunities to construct GRNs. Here, we propose a novel strategy to ... ...

    Abstract Identifying gene regulatory networks (GRNs) at the resolution of single cells has long been a great challenge, and the advent of single-cell multi-omics data provides unprecedented opportunities to construct GRNs. Here, we propose a novel strategy to integrate omics datasets of single-cell ribonucleic acid sequencing and single-cell Assay for Transposase-Accessible Chromatin using sequencing, and using an unsupervised learning neural network to divide the samples with high copy number variation scores, which are used to infer the GRN in each gene block. Accuracy validation of proposed strategy shows that approximately 80% of transcription factors are directly associated with cancer, colorectal cancer, malignancy and disease by TRRUST; and most transcription factors are prone to produce multiple transcript variants and lead to tumorigenesis by RegNetwork database, respectively. The source code access are available at: https://github.com/Cuily-v/Colorectal_cancer.
    MeSH term(s) Humans ; Gene Regulatory Networks ; Multiomics ; DNA Copy Number Variations ; Algorithms ; Transcription Factors/genetics ; Colorectal Neoplasms/genetics
    Chemical Substances Transcription Factors
    Language English
    Publishing date 2023-03-27
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2068142-2
    ISSN 1477-4054 ; 1467-5463
    ISSN (online) 1477-4054
    ISSN 1467-5463
    DOI 10.1093/bib/bbad011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Identification of Prognostic Biomarkers for Bladder Cancer Based on DNA Methylation Profile.

    Zhang, Shumei / Zhang, Jingyu / Zhang, Qichao / Liang, Yingjian / Du, Youwen / Wang, Guohua

    Frontiers in cell and developmental biology

    2022  Volume 9, Page(s) 817086

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2022-01-31
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2737824-X
    ISSN 2296-634X
    ISSN 2296-634X
    DOI 10.3389/fcell.2021.817086
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: ATP Citrate Lyase is a General Tumour Biomarker and Contributes to the Development of Cutaneous Squamous Cell Carcinoma.

    Luo, Ruiting / Huang, Yingjian / Bai, Ruimin / Liu, Meng / Sun, Liang / Wang, Xiaofei / Zheng, Yan

    Acta dermato-venereologica

    2024  Volume 104, Page(s) adv23805

    Abstract: ATP citrate lyase, the first rate-limiting enzyme in de novo lipogenesis, plays a crucial role in tumour progression. This study explores ATP citrate lyase's potential as a tumour biomarker and its role in cutaneous squamous cell carcinoma. ATP citrate ... ...

    Abstract ATP citrate lyase, the first rate-limiting enzyme in de novo lipogenesis, plays a crucial role in tumour progression. This study explores ATP citrate lyase's potential as a tumour biomarker and its role in cutaneous squamous cell carcinoma. ATP citrate lyase expression patterns were analysed using TCGA and TIMER databases, and patient skin specimens were collected for immunohistochemistry to determine ATP citrate lyase levels. Cell proliferation, cell cycle, apoptosis, and c-Myc expression were assessed in A431 and SCL-1 cells. Stable cell lines with reduced ATP citrate lyase expression were obtained and subcutaneously implanted into nude mice to evaluate in vivo tumour growth. Ki67, c-Myc expression and TUNEL staining were analysed in subcutaneous tumours. ATP citrate lyase exhibited upregulation in various tumours, and showed significant associations with prognosis and immune infiltrate. Moreover, ATP citrate lyase was highly expressed in cutaneous squamous cell carcinoma. After ATP citrate lyase silencing, cutaneous squamous cell carcinoma cell growth decelerated, the cell cycle halted, cell apoptosis increased, and c-Myc expression decreased. Animal experiments revealed that, following ATP citrate lyase knockdown, tumour tissue growth slowed down, and there was a reduction in Ki-67 and c-Myc expression, accompanied by enhanced TUNEL staining. In conclusion, ATP citrate lyase may serve as a tumour biomarker. It is highly expressed in cutaneous squamous cell carcinoma and may serve as a therapeutic target.
    MeSH term(s) Mice ; Animals ; Humans ; ATP Citrate (pro-S)-Lyase/genetics ; ATP Citrate (pro-S)-Lyase/metabolism ; Carcinoma, Squamous Cell/genetics ; Biomarkers, Tumor/genetics ; Mice, Nude ; Skin Neoplasms/genetics
    Chemical Substances ATP Citrate (pro-S)-Lyase (EC 2.3.3.8) ; Biomarkers, Tumor
    Language English
    Publishing date 2024-04-08
    Publishing country Sweden
    Document type Journal Article
    ZDB-ID 80007-7
    ISSN 1651-2057 ; 0001-5555
    ISSN (online) 1651-2057
    ISSN 0001-5555
    DOI 10.2340/actadv.v104.23805
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Screening for Chinese medical staff mental health by SDS and SAS during the outbreak of COVID-19.

    Liang, Yingjian / Chen, Meizhu / Zheng, Xiaobin / Liu, Jing

    Journal of psychosomatic research

    2020  Volume 133, Page(s) 110102

    Keywords covid19
    Language English
    Publishing date 2020-03-21
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 80166-5
    ISSN 1879-1360 ; 0022-3999
    ISSN (online) 1879-1360
    ISSN 0022-3999
    DOI 10.1016/j.jpsychores.2020.110102
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top